Survival, re-expansion and cell survival of human blastocysts following vitrification and warming using two vitrification systems

Lopes, A. S.; Frederickx, Veerle; Kerkhoven, G Van; Campo, Rudi; Puttemans, Patrick; Gordts, Stephan

doi:10.1007/s10815-014-0373-2

Cited by 17 publications

(11 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, a detrimental effect on the clinical results of a fresh embryo transfer on day 6 on an advanced endometrium cannot be completely excluded. Vitrification and warming of euploid biopsied blastocysts has been demonstrated to be a very safe and efficient method for embryo cryopreservation [16,17].…”

Section: Introductionmentioning

confidence: 99%

The endometrial preparation for frozen-thawed euploid blastocyst transfer: a prospective randomized trial comparing clinical results from natural modified cycle and exogenous hormone stimulation with GnRH agonist

Greco

Litwicka

Arrivi

et al. 2016

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose The aim of the study was to evaluate two methods of endometrial preparation for frozen-thawed single euploid blastocyst transfer: modified natural and artificial cycle with GnRH-agonist pituitary suppression. Methods In this prospective, controlled randomized trial, a total of 236 patients undergoing infertility treatment were randomized in 1:1 ratio; 118 received a frozen-thawed single euploid blastocyst transfer in a modified natural cycle and 118 in an artificial cycle with GnRH-agonist pituitary suppression. In the artificial protocol, GnRH-agonist combined with estradiol valerate was administered. In the natural protocol, only final oocyte maturation was induced using human chorionic gonadotropin administration. The primary end-points were the clinical pregnancy and implantation rates; the secondary end-points were the cost-benefit in terms of drug cost and the number of visits and the woman psychological distress caused by the treatment. Results No significant differences were found in clinical pregnancy, implantation, and miscarriage rates between protocols. The number of clinical and ultrasound controls and the number of laboratory dosages and venous samplings were similar in both study groups. No significant differences were found between the groups in the anxiety and depression values before the start of treatment, on the days of progesterone administration, the blastocyst transfer, and pregnancy test. Conclusions The findings of this study evidence that in case of frozen-thawed single euploid blastocyst transfer, both protocols are equally effective in terms of clinical outcomes, costbenefit, and patient compliance. The choice of endometrial preparation protocol should be based on women menstrual and ovulatory characteristics or otherwise on patient need for cycle planning. Trial registration www.clinicaltrials.gov with number NCT02378584

show abstract

Section: Introductionmentioning

confidence: 99%

The endometrial preparation for frozen-thawed euploid blastocyst transfer: a prospective randomized trial comparing clinical results from natural modified cycle and exogenous hormone stimulation with GnRH agonist

Greco

Litwicka

Arrivi

et al. 2016

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…Only one study [29] presented in vitro data (no clinical outcome data) comparing the cation system; post-warming survival, re-expansion, and numbers of cells in human blastocysts were found not to be significantly different between the two vitrification systems, and importantly, cell numbers were not significantly different between the two systems and compared to non-cryopreserved controls.…”

Section: Discussionmentioning

confidence: 99%

Large-volume vitrification of human biopsied and non-biopsied blastocysts: a simple, robust technique for cryopreservation

Reed¹,

Said²,

Thompson³

et al. 2014

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose To evaluate the transition from a proven slowcooling cryopreservation method to a commercial largevolume vitrification system for human blastocysts. Methods Retrospective analysis of de-identified laboratory and clinical data from January 2012 to present date for all frozen embryo replacement (FET) cycles was undertaken. Cryopreservation of trophectoderm-biopsied or non-biopsied blastocysts utilized during this time period was logged as either slow-cooling, small-volume vitrification, or largevolume vitrification. Blastocyst survival post-warm or postthaw, clinical pregnancy following FET, and implantation rates were identified for each respective cryopreservation method. Results Embryo survival was highest for large-volume vitrification compared to micro-volume vitrification and slowcooling; 187/193 (96.9 %), 27/32 (84.4 %), and 244/272 (89.7 %), respectively. Survival of biopsied and nonbiopsied blastocysts vitrified using the large-volume system was 105/109 (96.3 %) and 82/84 (97.6 %), respectively. Survival for micro-volume biopsied and non-biopsied blastocysts was 16/30 (83.3 %) and 2/2 (100.0 %) respectively. Slow-cooling post-thaw embryo survival was 272/244 (89.7 %). Clinical pregnancy and implantation rates outcomes for non-biopsied embryos were similar between large-volume and slow-cooling cryopreservation methods, 18/39 (46.2 %) clinical pregnancy and 24/82 (29.3 %) implantation/embryo, and 52/116 (44.8 %) clinical pregnancy and 67/244 (27.5 %) implantation/embryo, respectively. Comparing outcomes for biopsied embryos, clinical pregnancy and implantation rates were 39/67 (58.2 %) clinical pregnancy and 50/105 (47.6 %) implantation/embryo and 4/16 (25 %) clinical pregnancy and 6/25 (24.0 %) implantation/embryo, respectively. Conclusions The LifeGlobal large-volume vitrification system proved to be very reliable, simple to learn and implement in the laboratory. Clinically large-volume vitrification was as, or more effective compared to slow-cooling cryopreservation in terms of recovery of viable embryos in this laboratory.

show abstract

“…One clear advantage that IVF centers have over those only involved in long-term sperm banking is in the continuous demonstration of the effectiveness of their procedures. Vitrification procedures are now providing recovery rates in excess of 85 to 90% for both oocytes and blastocysts, 34,35 which in turn translate into successful pregnancies. Performance testing the process of cryopreservation is therefore relatively straightforward since any significant reduction in recovery or pregnancy rate would prompt investigation of conditions during the addition of cryoprotectants, cooling, and storage.…”

Section: Risk and The Quality Of Frozen-thawed Materialsmentioning

confidence: 99%

Safe Storage of Gametes and Embryos: No Time for Complacency

Tomlinson¹

2018

Semin Reprod Med

View full text Add to dashboard Cite

Recent serious untoward incidents in the field of assisted reproduction have once again highlighted the need for vigilance and in particular improved risk management in relation to the cryopreservation of gametes and embryos. Despite increasing levels of regulation and the requirement to adhere to total quality management practices, catastrophic incidents such as the death of an employee or the loss of a freezer full of patient embryos or sperm continue to occur sufficiently frequently for the industry to be concerned and highlight the need to make practices considerably safer. Potential losses through litigation could be considerable if the gamete or embryo bank is found to be negligent and fails to provide the necessary resources and implement recognizable control measures, which may include suitable facilities with adequate ventilation and oxygen monitoring, competent staff, and an appropriate level of well-maintained equipment; round-the-clock emergency procedures, early warning systems to deal with a failing vessel; and contingency to mitigate losses within a failing vessel and validated procedures which are embedded into the organization which lead to a high-quality end product, for example, frozen embryo while permitting a safe system of work. Since cross-contamination incidents have occurred in other disciplines such as blood cryostorage, which have led to the transmission of viral disease, the biological safety of the end product also requires careful consideration despite the fact that no similar incident appears to have come to light in the field of reproductive medicine. Implementation of risk reduction measures may include screening for blood borne viruses and possibly bacterial infection, careful selection of appropriate packaging plastics, and consideration as to whether packaging is suitable for immersion in liquid nitrogen. If not, vapor phase storage may be considered as additional mitigation. In the light of recent events, centers should place risk management of their cryofacilities and service high on the agenda and ensure that it becomes integral to future objective setting and business planning.

show abstract

Survival, re-expansion and cell survival of human blastocysts following vitrification and warming using two vitrification systems

Cited by 17 publications

References 26 publications

The endometrial preparation for frozen-thawed euploid blastocyst transfer: a prospective randomized trial comparing clinical results from natural modified cycle and exogenous hormone stimulation with GnRH agonist

The endometrial preparation for frozen-thawed euploid blastocyst transfer: a prospective randomized trial comparing clinical results from natural modified cycle and exogenous hormone stimulation with GnRH agonist

Large-volume vitrification of human biopsied and non-biopsied blastocysts: a simple, robust technique for cryopreservation

Safe Storage of Gametes and Embryos: No Time for Complacency

Contact Info

Product

Resources

About